Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars

  • Marco van de Weert
  • Eva Horn Møller
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume VIII)


Danger Signal Therapeutic Protein Innovator Product Glycosylation Pattern Polysialic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bachmann, M. F. and Zinkernagel, R. M. 1997. Neutralizing antiviral B cell responses. Ann. Rev. Immunol. 15:235–270.CrossRefGoogle Scholar
  2. Bardor, M., Faveeuw, C., Fitchette, A. C., Gilbert, D., Galas, L., Trottein, F., Faye, L., and Lerouge, P. 2003. Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xylose. Glycobiology 13:427–434.PubMedCrossRefGoogle Scholar
  3. Beers, D. O. and Tsang, L. 2007. US rules on biosimilars – what has changed? Access date August 2007.Google Scholar
  4. Belsey, M. J., Harris, L. M., Das, R. R., and Chertkow, J. 2006. Biosimilars: initial excitement gives way to reality. Nat. Rev. Drug Discov. 5:535–536.PubMedCrossRefGoogle Scholar
  5. Benatuil, L., Kaye, J., Rich, R. F., Fishman, J. A., Green, W. R., and Iacomini, J. 2005. The influence of natural antibody specificity on antigen immunogenicity. Eur. J. Immunol. 35:2638–2647.PubMedCrossRefGoogle Scholar
  6. Bhanot, G. 2004. Results from modeling of B-cell receptors binding to antigen. Progress Biophys. Mol. Biol. 85:343–352.CrossRefGoogle Scholar
  7. Binolfi, A., Rasia, R. M., Bertoncini, C. W., Ceolin, M., Zweckstetter, M., Griesinger, C., Jovin, T. M., and Fernandez, C. O. 2006. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J. Am. Chem. Soc. 128:9893–9901.PubMedCrossRefGoogle Scholar
  8. Bolgiano, B., Mawas, F., Yost, S. E., Crane, D. T., Lemercinier, X., and Corbel, M. J. 2001. Effect of physico-chemical modification on the immunogenicity of Haemophilus influenza type b oligosaccharide-CRM197 conjugate vaccines. Vaccine 19:3189–3200.PubMedCrossRefGoogle Scholar
  9. Brooks, S. A. 2004. Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system. Mol. Biotechnol. 28:241–255.PubMedCrossRefGoogle Scholar
  10. Chamberlain, P. 2004. Biogenerics: Europe takes another step forward while the FDA dives for cover. Drug Discov. Today 9:817–820.PubMedCrossRefGoogle Scholar
  11. Cheifetz, A. and Mayer, L. 2005. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt. Sinai J. Med. 72:250–256.PubMedGoogle Scholar
  12. Chi, E. Y., Krishnan, S., Randolph, T. W., and Carpenter, J. F. 2003. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 20:1325–1336.PubMedCrossRefGoogle Scholar
  13. Christensen, S., Moeller, E. H., Bonde, C., and Lilleoere, A. M. 2007. Preliminary studies of the physical stability of a glucagon-like peptide-1 derivate in the presence of metal ions. Eur. J. Pharm. Biopharm. 66:366–371.PubMedCrossRefGoogle Scholar
  14. Cobb, B. A. and Kasper, D. L. 2005. Coming of age: carbohydrates and immunity. Eur. J. Immunol. 35:352–356.PubMedCrossRefGoogle Scholar
  15. Dintzis, R. Z., Okajima, M., Middleton, M. H., Greene, G., and Dintzis, H. M. 1989. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J. Immunol. 143:1239–1244.PubMedGoogle Scholar
  16. Dove, A. 2001. Betting on biogenerics. Nat. Biotech. 19:117–120.CrossRefGoogle Scholar
  17. EMEA. 2005. Guideline on similar biological medicinal products. CHMP/437/04.Google Scholar
  18. EMEA. 2006a. European public assessment report (EPAR) – Omnitrope. EMEA/H/C/607.Google Scholar
  19. EMEA. 2006b. European public assessment report (EPAR) – Valtropin. EMEA/H/C/602.Google Scholar
  20. EMEA. 2006c. Questions and answers on recommendation for refusal of marketing application for Alpheon. EMEA/190896/2006.Google Scholar
  21. Gregoriadis, G., Jain, S., Papaioannou, I., and Laing, P. 2005. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int. J. Pharm. 300:125–130.PubMedCrossRefGoogle Scholar
  22. Gribben, J. G., Devereux, S., Thomas, N. S., Keim, M., Jones, H. M., Goldstone, A. H., and Linch, D. C. 1990. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335:434–437.PubMedCrossRefGoogle Scholar
  23. Heavner, G. A. 2006. Rebuttal letter. Pharm. Res. 23:643–644.CrossRefGoogle Scholar
  24. Hermeling, S., Crommelin, D. J. A., Schellekens, H., and Jiskoot, W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21:897–903.PubMedCrossRefGoogle Scholar
  25. Hermeling, S., Schellekens, H., Crommelin, D. J. A., and Jiskoot, W. 2003. Micelle-associated protein in epoietin formulations: a risk factor for immunogenicity? Pharm. Res. 20:1903–1907.PubMedCrossRefGoogle Scholar
  26. Hermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., and Jiskoot, W. 2006. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm. Sci. 95:1084–1096.PubMedCrossRefGoogle Scholar
  27. Hwang, W. Y. K., and Foote, J. 2005. Immunogenicity of engineered antibodies. Methods 36:3–10.PubMedCrossRefGoogle Scholar
  28. Ishida, T., Ichihara, M., Wang, X. Y., and Kiwada, H. 2006a. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 115:243–250.CrossRefGoogle Scholar
  29. Ishida, T., Ichihara, M., Wang, X. Y., Yamamoto, K., Kimura, J., Majima, E., and Kiwada, H. 2006b. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 112:15–25.CrossRefGoogle Scholar
  30. Judge, A., McClintock, K., Phelps, J. R., and MacLachlan, I. 2006. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 13:328–337.PubMedCrossRefGoogle Scholar
  31. Klinmann, D. M., Xie, H., and Ivins, B. E. 2006. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann. N. Y. Acad. Sci. 1082:137–150.CrossRefGoogle Scholar
  32. Lerouge, P., Bardor, M., Pagny, S., Gomord, V., and Faye, L. 2000. N-glycosylation of recombinant pharmaceutical glycoproteins produced in transgenic plants: towards an humanisation of plant N-glycans. Curr. Pharm. Biotechnol. 1:347–354.PubMedCrossRefGoogle Scholar
  33. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., and Kuter, D. J. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241–3248.PubMedCrossRefGoogle Scholar
  34. Lundberg, K., Nijenhuis, S., Vossenaar, E. R., Palmblad, K., van Venrooij, W. J., Klareskog, L., Zendman, A. J., and Harris, H. E. 2005. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res. Ther. 7:R458–R467.PubMedCrossRefGoogle Scholar
  35. Maas, C., Hermeling, S., Bouma, B., Jiskoot, W., and Gebbink, M. F. B. G. 2007. A role for protein misfolding in immunogenicity of biopharmaceuticals. J. Biol. Chem. 282:2229–2236.PubMedCrossRefGoogle Scholar
  36. Narhi, L. O., Arakawa, T., Aoki, K., Wen, J., Elliott, S., Boone, T., and Cheetham, J. 2001. Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin. Protein Eng 14:135–140.PubMedCrossRefGoogle Scholar
  37. Ohmori, H., and Kanayama, N. 2005. Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins. Autoimmun. Rev. 4:224–229.PubMedCrossRefGoogle Scholar
  38. Presta, L. G. 2006. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 58:640–656.PubMedCrossRefGoogle Scholar
  39. Purohit, V. S., Middaugh, C. R., and Balasubramanian, S. V. 2006. Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia A mice. J. Pharm. Sci. 95:358–371.PubMedCrossRefGoogle Scholar
  40. Rosenberg, A. S. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J. 8(3):59.CrossRefGoogle Scholar
  41. Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., and Goelz, S. E. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res. 15:641–649.PubMedCrossRefGoogle Scholar
  42. Schellekens, H. 2002a. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. 1:457–462.Google Scholar
  43. Schellekens, H. 2002b. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Therap. 24:1720–1740.CrossRefGoogle Scholar
  44. Schellekens, H. 2004. How similar do ‘biosimilars’ need to be? Nat. Biotech. 22:1357–1359.CrossRefGoogle Scholar
  45. Schellekens, H., and Casadevall, N. 2004. Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. 251:II/4–II/9.CrossRefGoogle Scholar
  46. Schellekens, H., and Jiskoot, W. 2006. Eprex-associated pure red cell aplasia and leachates. Nat. Biotech. 24:613–614.CrossRefGoogle Scholar
  47. Schlee, M., Hornung, V., and Hartmann, G. 2006. siRNA and isRNA: two edges of one sword. Mol. Ther. 14:463–470.PubMedCrossRefGoogle Scholar
  48. Semple, S. C., Harasym, T. O., Clow, K. A., Ansell, S. M., Klimuk, S. K., and Hope, M. J. 2005. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J. Pharmacol. Exp. Therap. 312:1020–1026.CrossRefGoogle Scholar
  49. Sharma, B. 2007a. Immunogenicity of therapeutic proteins. Part 1: impact of product handling. Biotechnol. Adv. 25:310–317.CrossRefGoogle Scholar
  50. Sharma, B. 2007b. Immunogenicity of therapeutic proteins. Part 2: impact of container closures. Biotechnol. Adv. 25:318–324.CrossRefGoogle Scholar
  51. Sharma, B. 2007c. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. Biotechnol. Adv. 25:325–331.CrossRefGoogle Scholar
  52. Sharma, B., Bader, F., Templeman, T., Lisi, P., Ryan, M., and Heavner, G. A. 2004. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex. Eur. J. Hosp. Pharm. 5:86–91.Google Scholar
  53. Siddiqui, N. I., Idakieva, K., Demarsin, B., Doumanova, L., Compernolle, F., and Gielens, C. 2007. Involvement of glycan chains in the antigenicity of Rapana thomasiana hemocyanin. Biochem. Biophys. Res. Commun. 361:705–711.PubMedCrossRefGoogle Scholar
  54. Sinclair, A. M., and Elliott, S. 2005. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94:1626–1635.PubMedCrossRefGoogle Scholar
  55. Smith, M. L., Lindbo, J. A., Dillard-Telm, S., Brosio, P. M., Lasnik, A. B., McCormick, A. A., Nguyen, L. V., and Palmer, K. E. 2006. Modified Tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 348:475–488.PubMedCrossRefGoogle Scholar
  56. Sulzer, B. and Perelson, A. S. 1997. Immunons revisited: binding of multivalent antigens to B cells. Mol. Immunol. 34:63–74.PubMedCrossRefGoogle Scholar
  57. Tsuda, E., Kawanishi, G., Ueda, M., Masuda, S., and Sasaki, R. 1990. The role of carbohydrate in recombinant human erythropoietin. Eur. J. Biochem. 188:405–411.PubMedCrossRefGoogle Scholar
  58. Veronese, F. M., and Pasut, G. 2005. PEGylation, successful approach to drug delivery. Drug Discov. Today 10:1451–1458.PubMedCrossRefGoogle Scholar
  59. Wang, W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289:1–30.PubMedCrossRefGoogle Scholar
  60. Wang, X. Y., Ishida, T., Ichihara, M., and Kiwada, H. 2005. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J. Control. Release 104:91–102.PubMedCrossRefGoogle Scholar
  61. Weiner, L. M. 2006. Fully human therapeutic monoclonal antibodies. J. Immunother. 29:1–9.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2008

Authors and Affiliations

  • Marco van de Weert
  • Eva Horn Møller

There are no affiliations available

Personalised recommendations